CD19/CD22 CAR-T
Phase 2Cell therapy
CD19/CD22 CAR-T is one of 60 small molecule programs targeting Lymphoma. It is currently in Phase 2.
2
Indications
5
Total Trials
1
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Blenoxane
SSequus Pharmaceuticals
Preclinical
Oncaspar
SServier
Preclinical
Zofran
NovartisPreclinical
CD19/CD22 CAR-T
HHebei Senlang Biotechnology Inc., Ltd.
Phase 2
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
PEG-Intron
Merck & Co.Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Treatment1 trial
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
Active, not recruiting·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 1/2·NCT04499573·50 enrolled
Allogeneic Hematopoietic Stem Cell Transplantation1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CD19/CD22 CAR-T. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details